<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655083</url>
  </required_header>
  <id_info>
    <org_study_id>NIC 02</org_study_id>
    <secondary_id>Oral absorption</secondary_id>
    <secondary_id>of Nepadutant in Infants</secondary_id>
    <nct_id>NCT00655083</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants</brief_title>
  <official_title>Pilot Study to Evaluate the Oral Absorption, Safety, and Tolerability of Nepadutant Administered as Single Oral Doses to Infants With Colic and Other Functional Gastrointestinal Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the gastrointestinal absorption of nepadutant after
      single dose as oral solution (and the effect of age on its oral absorption) in infants. Oral
      absorption is evaluated through the drug recovery in urine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to evaluate the oral adsorption of nepadutant (0.1 or 0.5 mg/Kg given as one
      single dose as oral solution) in infants divided in three age strata (from 6 to 24 weeks
      old). Oral absorption is evaluated by measuring the amount of nepadutant in the urine output
      collected during the 24 hours after oral administration with special diapers.

      Safety and tolerability of the drug will be evaluated by monitoring any changes in
      signs/symptoms at medical examination and vital signs during the fist 4 hours post-dose in
      the Hospital site and then by the parents at home up to 24 hours and 1 week post nepadutant
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.</measure>
    <time_frame>24 hours</time_frame>
    <description>Nepadutant was measured in the 24-h urine collection post both doses (0.1 and 0.5 mg/kg dose), in the age strata 6-&lt;12 and 12-&lt;18 weeks, using urinary collection/extraction from pre-weighed special fiber based diapers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.</measure>
    <time_frame>24 hours</time_frame>
    <description>Nepadutant was measured in the 24-h urine collection post both doses (0.1 and 0.5 mg/kg dose), in the age stratum 18-24 weeks, using urinary collection/extraction from pre-weighed special fiber based diapers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events After Administration of Single Oral Doses up to 0.5 mg/kg of Nepadutant in Infants.</measure>
    <time_frame>one week</time_frame>
    <description>Number of adverse events (AE) reported by dose and age stratum 6-&lt;12 and 12-&lt;18 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events After Administration of Single Oral Doses up to 0.5 mg/kg of Nepadutant in Infants.</measure>
    <time_frame>one week</time_frame>
    <description>Number of adverse events (AE) reported by dose and age stratum 18-24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Infantile Colic</condition>
  <condition>Infantile Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepadutant 0.1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepadutant 0.5 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepadutant</intervention_name>
    <description>0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepadutant</intervention_name>
    <description>0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible for inclusion in the study if they meet all of the following
        criteria:

          -  Infants with a history consistent with a diagnosis of colic or other functional
             gastrointestinal disorders

          -  Age &gt;6 weeks and &lt; 24 weeks

          -  At least 44 weeks post-conceptual age at enrolment

          -  Normal growth

          -  Informed consent by parents (one or both) or legal guardian

          -  Caregiver available to be trained in collection and storage of used diapers

          -  Caregiver available to record feeding episodes and defecations on the diary

        Exclusion Criteria:

        Subjects will be excluded from the study if they meet any of the following criteria:

          -  Clinical evidence of major cardiovascular, respiratory, renal, hepatic, endocrine,
             metabolic, gastrointestinal (excluding infantile colic and other functional
             gastrointestinal disorders, unless associated to symptoms which are likely to
             interfere with drug absorption, e.g. frequent vomiting), haematological, severe
             dermatological or neurological pathology or other diseases;

          -  Previous major surgery or blood loss

          -  Intake of antimuscarinic drugs, simethicone, or dimethicone 24 hours before study
             treatment administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>24 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Blumer, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Rsearch Unit University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2008</study_first_posted>
  <results_first_submitted>May 27, 2010</results_first_submitted>
  <results_first_submitted_qc>August 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2010</results_first_posted>
  <last_update_submitted>October 11, 2011</last_update_submitted>
  <last_update_submitted_qc>October 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infantile colic</keyword>
  <keyword>Abdominal Cramps</keyword>
  <keyword>Colicky Pain</keyword>
  <keyword>Functional gastrointestinal disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MEN 11420</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period extended from March 2008 to May 2009 at three Hospital Clinics</recruitment_details>
      <pre_assignment_details>Twenty out of the 21 enrolled infants were treated with study medication (1 infant did not attend the clinic after screening). NOTE: although the goal was to enroll 24 subjects, slow subject enrollment and expired drug restricted enrollment to 20 subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nepadutant 0.1 mg/kg</title>
          <description>Nepadutant 0.1 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Nepadutant 0.5 mg/kg</title>
          <description>Nepadutant 0.5 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nepadutant 0.1 mg/kg</title>
          <description>Nepadutant 0.1 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Nepadutant 0.5 mg/kg</title>
          <description>Nepadutant 0.5 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age Group 6 to &lt;12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Group 12 to &lt;18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Group 18 to 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.</title>
        <description>Nepadutant was measured in the 24-h urine collection post both doses (0.1 and 0.5 mg/kg dose), in the age strata 6-&lt;12 and 12-&lt;18 weeks, using urinary collection/extraction from pre-weighed special fiber based diapers.</description>
        <time_frame>24 hours</time_frame>
        <population>Urinary drug concentration was analysed by dose and age stratum of the infants (6-&lt;12 and 12- &lt;18 weeks of age). Imputation technique was adopted for urine samples highly contaminated by faeces.</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant 0.1 mg/kg</title>
            <description>Nepadutant 0.1 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant 0.5 mg/kg</title>
            <description>Nepadutant 0.5 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.</title>
          <description>Nepadutant was measured in the 24-h urine collection post both doses (0.1 and 0.5 mg/kg dose), in the age strata 6-&lt;12 and 12-&lt;18 weeks, using urinary collection/extraction from pre-weighed special fiber based diapers.</description>
          <population>Urinary drug concentration was analysed by dose and age stratum of the infants (6-&lt;12 and 12- &lt;18 weeks of age). Imputation technique was adopted for urine samples highly contaminated by faeces.</population>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6- &lt;12 week old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5041" spread="7081"/>
                    <measurement group_id="O2" value="6474" spread="2463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12- &lt; 18 week old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2095" spread="1151"/>
                    <measurement group_id="O2" value="3727" spread="2845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events After Administration of Single Oral Doses up to 0.5 mg/kg of Nepadutant in Infants.</title>
        <description>Number of adverse events (AE) reported by dose and age stratum 6-&lt;12 and 12-&lt;18 weeks.</description>
        <time_frame>one week</time_frame>
        <population>Number of adverse events by dose and age strata (6-&lt;12 and 12- &lt;18 weeks of age) are reported by system organ class and preferred term.</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant 0.1 mg/kg</title>
            <description>Nepadutant 0.1 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant 0.5 mg/kg</title>
            <description>Nepadutant 0.5 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events After Administration of Single Oral Doses up to 0.5 mg/kg of Nepadutant in Infants.</title>
          <description>Number of adverse events (AE) reported by dose and age stratum 6-&lt;12 and 12-&lt;18 weeks.</description>
          <population>Number of adverse events by dose and age strata (6-&lt;12 and 12- &lt;18 weeks of age) are reported by system organ class and preferred term.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6- &lt;12 week old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12- &lt; 18 week old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.</title>
        <description>Nepadutant was measured in the 24-h urine collection post both doses (0.1 and 0.5 mg/kg dose), in the age stratum 18-24 weeks, using urinary collection/extraction from pre-weighed special fiber based diapers.</description>
        <time_frame>24 hours</time_frame>
        <population>Urinary drug concentration was analysed by dose and age stratum of the infants (18-24 weeks of age). Imputation technique was adopted for urine samples highly contaminated by faeces.</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant 0.1 mg/kg</title>
            <description>Nepadutant 0.1 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant 0.5 mg/kg</title>
            <description>Nepadutant 0.5 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.</title>
          <description>Nepadutant was measured in the 24-h urine collection post both doses (0.1 and 0.5 mg/kg dose), in the age stratum 18-24 weeks, using urinary collection/extraction from pre-weighed special fiber based diapers.</description>
          <population>Urinary drug concentration was analysed by dose and age stratum of the infants (18-24 weeks of age). Imputation technique was adopted for urine samples highly contaminated by faeces.</population>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1127" spread="1032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events After Administration of Single Oral Doses up to 0.5 mg/kg of Nepadutant in Infants.</title>
        <description>Number of adverse events (AE) reported by dose and age stratum 18-24 weeks.</description>
        <time_frame>one week</time_frame>
        <population>Number of adverse events by dose and age stratum (18-24 weeks of age) are reported by system organ class and preferred term.</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant 0.1 mg/kg</title>
            <description>Nepadutant 0.1 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant 0.5 mg/kg</title>
            <description>Nepadutant 0.5 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events After Administration of Single Oral Doses up to 0.5 mg/kg of Nepadutant in Infants.</title>
          <description>Number of adverse events (AE) reported by dose and age stratum 18-24 weeks.</description>
          <population>Number of adverse events by dose and age stratum (18-24 weeks of age) are reported by system organ class and preferred term.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded after 24 hours after dosing and at 1 week final follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nepadutant 0.1 mg/kg</title>
          <description>Nepadutant 0.1 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Nepadutant 0.5 mg/kg</title>
          <description>Nepadutant 0.5 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>middle ear infection</sub_title>
                <description>mild, unlikely treatment related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <description>mild, possibly tretment related, 2 days after dosing lasting &lt; 1 day</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>mild, unlikely treatment related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>hard stools</sub_title>
                <description>mild, possibly treatment related, 2 hours post dosing and lasting up to the following day</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <description>mild, unlikely treatment related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>mild, unlikely treatment related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis by diaper</sub_title>
                <description>mild, unlikely treatment related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No infants aged 18-24 weeks were dosed at 0.5 mg/kg dose when the trial was stopped because of slow recruitment and drug expiration.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Angela Capriati, Clinical research Director</name_or_title>
      <organization>Menarini Group- Clinical Research</organization>
      <phone>+ 39-055 56809990</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

